Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms

Shi, Dayu; Shi, Hongxia; Liu, Xiaoli; Duan, Minghui; Zhuang, Junling; Du, Xin; Qin, Ling; Hui, Wuhan; Liang, Rong; Wang, Meifang; Chen, Ye; Li, Dongyun; Yang, Wei; Tang, Gusheng; Zhang, Weihua; Kuang, Xia; Su, Wei; Han, Yanqiu; Chen, Limei; Xu, Jihong; Liu, Zhuogang; Huang, Jian; Zhao, Chunting; Tong, Hongyan; Hu, Jianda; Chen, Chunyan; Chen, Xiequn; Xiao, Zhijian^*; Jiang, Qian^*

Science Citation Index Expanded

北京大学; 南方医科大学; 青岛大学; 山东大学; 内蒙古医学院; 浙江大学; 苏州大学; 西安交通大学; 西北大学; 中国人民解放军第四军医大学; 中国医科大学; 中国医学科学院; 中国医学科学院北京协和医院; 1

摘要

We explored variables associated with patient-reported outcomes (PROs) including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and health-related quality of life in 1500 respondents with myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) in a multicenter, cross-sectional study across China, a representative of the developing countries. In multivariate analyses, urban household registration and higher education level were significantly-associated with no symptoms at diagnosis in respondents with ET or MF. CALR mutation was significantly-associated with lower MPN-10 scores in respondents with MF. Higher MPN-10 scores were significantly-associated with negative impact on daily life and work as well as lower satisfaction level in respondents with ET, PV and MF. Receiving ruxolitinib was significantly-associated with high satisfaction and satisfaction in respondents with MF. In addition, other demographics and clinical variables were also impacting PROs.

关键词

Myeloproliferative neoplasm patient-reported outcome CALR mutation MPN-10 ruxolitinib